Navigation Links
Massachusetts General Hospital leading nationwide, comparative study of common bipolar medications
Date:1/20/2011

The Massachusetts General Hospital (MGH) Bipolar Clinic and Research Program with the Bipolar Trials Network is launching Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness), a 10-site nationwide trial evaluating the real-world advantages and disadvantages of quetiapine, a widely prescribed second generation antipsychotic mood stabilizing medication, compared to lithium, the gold standard mood stabilizer, for the treatment of outpatients with bipolar disorder. The study is funded by a $10 million grant from the Agency for Healthcare Research Quality (AHRQ).

Bipolar disorder is a lifelong and highly recurrent mood disorder characterized by episodes of mania or hypomania that alternate with episodes of major depression. It is among the top 10 causes of disability worldwide, with associated costs of $70.6 billion per year for treatment and prevention.

"Studies that compare treatments for bipolar disorder usually don't allow participants to take other medications, but most patients need about three medications to feel well and stay well. Bipolar CHOICE is unique because participants can be treated not only with quetiapine or lithium, but with almost any other medication except other antipsychotics in order to help them feel better," says Andrew A. Nierenberg, MD, director of the MGH Bipolar Research Program and the principal investigator of Bipolar CHOICE.

Over the past 10 years, the pharmacologic treatments for bipolar disorder have shifted away from lithium which is available as a generic medication in favor of newly developed antipsychotics, such as quetiapine. Both drugs have well documented side effects. Quetiapine has the risk of drowsiness, weight gain, and increases the risk of cardiovascular disease. Lithium is associated with the risk of long-term thyroid and kidney problems.

"A real-world effectiveness study may uncover considerable differences regarding the risks of adverse effects, costs, and adherence to treatment. If such differences are found, the results of this study would have immediate and profound implications for clinical treatment decisions," says Louisa Sylvia, PhD, director of Clinical Operations of Bipolar CHOICE.

The AHRQ grant is part of an investments made under the American Recovery and Reinvestment Act of 2009, which designated $1.1. billion to support patient-centered outcomes research. This research is designed to inform health care decisions by providing evidence and information on the effectiveness, benefits and harms of different treatment options.


'/>"/>

Contact: Jennifer Gundersen Harris
jgundersen1@partners.org
617-724-6433
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Massachusetts Hospital Agrees to Pay U.S. $2.79 Million to Resolve False Claims Act Allegations
2. Diabetics Twice as Likely to Have Hearing Loss; Massachusetts HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March
3. Elements Therapeutic Massage Announces Franchise Expansion Plan for Massachusetts
4. Miles for Hope’s Moving Towards A Cure(SM) Brain Tumor Walk in Boston Raising Funds for Brain Tumor Vaccine and Massachusetts General Hospital
5. Massachusetts health care reform reviewed as a model for national plan
6. Firefighters Walk Over 60,000 Miles in Blue Cross Blue Shield of Massachusetts' Fitness Challenge
7. Blue Cross Blue Shield of Massachusetts Demonstrates Community Commitment with Fifth William C. Van Faasen Community Service Sabbatical
8. Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract
9. Doctors hard to find for patients in Massachusetts first for-profit health plan
10. Massachusetts Institute of Technology IDs new cancer drug target
11. Massachusetts physician groups improving patient experience, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... (BIAA) is collaborating with a New England student to educate the public on ... acclaim in 2016 for launching the first-ever National Concussion Awareness Day. , Brooke ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... recently launched community enrichment program. Partnering once again with Boys & Girls Clubs ... to help find the area’s very own American Idol. With all proceeds benefitting ...
(Date:8/16/2017)... ... , ... LabRoots , the leading provider of educational and interactive virtual ... announce Andrew Ly as the winner of the LabRoots Summer Textbook scholarship, awarding him ... who is in his third year at the University of California, Los Angeles majoring ...
(Date:8/16/2017)... ... 2017 , ... Melbourne’s reign as the world’s most liveable city has been ... Liveability Index. , The Index surveys 140 of the world’s cities and Melbourne has ... consistently come in the top three of the index. So what is it that ...
(Date:8/16/2017)... ... August 16, 2017 , ... Connexion Point, a technology-enabled healthcare services company ... fourth consecutive year. With 197% revenue growth over the past three years, ... growing companies. , Previous honors include ranking 86th on the Inc. 500 ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO), is now dispensing ... residents. Naloxone is available without a prescription ... G-3320 Beecher Road. ... is intended to block or reverse the effects of ... consciousness. The medication is often carried by first responders ...
(Date:8/11/2017)... Aug. 11, 2017 DarioHealth Corp. (NASDAQ: DRIO), ... and big data solutions, today announced that it will ... 14 and host a conference call at 9:00am ET. ... and financial results and its strategy and outlook for ... by Erez Raphael , Chief Executive Officer, and ...
(Date:8/7/2017)... , Aug. 7, 2017 Zimmer Biomet Holdings, Inc. ... today announced that its Board of Directors has approved the ... third quarter of 2017. ... on or about October 27, 2017 to stockholders of record ... Future declarations of dividends are subject to approval of the ...
Breaking Medicine Technology: